Publicité
Publicité

BRTX

BRTX logo

BioRestorative Therapies, Inc. Common Stock (NV)

1.21
USD
Sponsorisé
+0.01
+0.42%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

1.21

0.00
0.00%

BRTX Rapports sur les bénéfices

Ratio de surprise positive

BRTX a dépassé 12 des 15 dernières estimations.

80%

Prochain rapport

Date du prochain rapport
25 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$306.00K
/
-$0.38
Variation implicite de Q3 25 (Revenue/ EPS)
+2450.00%
/
+15.15%
Variation implicite de Q4 24 (Revenue/ EPS)
+606.70%
/
+90.00%

BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue

On 12 nov. 2025, BRTX reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 10.13% surprise. Revenue reached 12.00 mille, compared to an expected 469.20 mille, with a -97.44% difference. The market reacted with a -9.42% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analystes forecast an EPS of -0.38 USD, with revenue projected to reach 306.00 mille USD, implying an hausse of 15.15% EPS, and hausse of 2450.00% in Revenue from the last quarter.
FAQ
For Q3 2025, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of -$0.33, beating estimates by 10.13%, and revenue of $12.00K, -97.44% below expectations.
The stock price moved down -9.42%, changed from $1.38 before the earnings release to $1.25 the day after.
The next earning report is scheduled for 25 mars 2026.
Based on 4 analystes, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.38 and revenue of $306.00K for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité